Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations an...
2023-10-12 17:48:17 ET Gainers: Comtech Telecommunications ( CMTL ) +14% . Relay Therapeutics ( RLAY ) +12% . Ovid Therapeutics ( OVID ) +6% . Groupon ( GRPN ) +5% . Omeros Corporation ( OMER ) +4% . Losers: O...
2023-10-09 09:48:33 ET Summary Sutro Biopharma is advancing its lead candidate, luvelta, for the treatment of various types of cancer, with a focus on ovarian and endometrial cancers. The company will present results from a phase 1b study using luvelta to treat endometrial cancer ...
2023-10-06 13:54:23 ET More on ImmunoGen ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty? ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade) ImmunoGen, Inc. (IMGN) Q2 2023 Earnings Call Transcript ImmunoGen appoin...
2023-10-06 12:20:23 ET More on Sutro Biopharma Sutro BioPharma: Good Stewardship Through Early Trials Seeking Alpha’s Quant Rating on Sutro Biopharma Historical earnings data for Sutro Biopharma Financial information for Sutro Biopharma For fur...
2023-10-05 17:23:44 ET Gainers: nCino ( NASDAQ: NCNO ) +8% . TPI Composites ( TPIC ) +6% . SCYNEXIS ( SCYX ) +5% . Sutro Biopharma ( STRO ) +5% . Black Diamond Therapeutics ( BDTX ) +4% . Losers: SomaLogic ( SLGC ...
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as...
2023-09-14 13:21:48 ET Summary Sutro is developing mainly antibody-drug conjugates to address solid tumors. Their flagship molecule has shown both encouraging efficacy and concerning toxicity. The company has strengthened their balance sheet strategically, removing the short-t...
2023-08-11 04:02:55 ET Sutro Biopharma press release ( NASDAQ: STRO ): Q2 GAAP EPS of -$0.64 beats by $0.07 . Revenue of $10.4M (-63.0% Y/Y) misses by $3.2M . As of June 30, 2023, Sutro had cash and investments of $358.3 million and shares of Vaxcyte common sto...
- Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial cancers as a Mini Oral Se...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., a...
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with be...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...